Angioimmunoblastic T-cell Lymphoma Clinical Trials

9 recruitingLast updated: June 18, 2026

There are 9 actively recruiting angioimmunoblastic t-cell lymphoma clinical trials across 6 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include New York, New York, United States, Houston, Texas, United States, New Haven, Connecticut, United States. Updated daily from ClinicalTrials.gov.


Angioimmunoblastic T-cell Lymphoma Trials at a Glance

9 actively recruiting trials for angioimmunoblastic t-cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in New York, Houston, and New Haven. Lead sponsors running angioimmunoblastic t-cell lymphoma studies include National Cancer Institute (NCI), The Affiliated Hospital of Xuzhou Medical University, and Mayo Clinic.

Browse angioimmunoblastic t-cell lymphoma trials by phase

Treatments under study

About Angioimmunoblastic T-cell Lymphoma Clinical Trials

Looking for clinical trials for Angioimmunoblastic T-cell Lymphoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Angioimmunoblastic T-cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Angioimmunoblastic T-cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting

A Registry for People With T-cell Lymphoma

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+27 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141
Recruiting
Phase 3

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Lymphoma, T-CellPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc.150 enrolled34 locationsNCT06561048
Recruiting
Phase 1

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

T-cell LymphomaAnaplastic Large Cell LymphomaAdult T-cell Leukemia/Lymphoma+3 more
National Cancer Institute (NCI)20 enrolled1 locationNCT07388563
Recruiting
Phase 1

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.255 enrolled17 locationsNCT06393738
Recruiting
Phase 1

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

T-cell LymphomaPeripheral T Cell LymphomaMycosis Fungoides+8 more
SciTech Development, Inc.46 enrolled10 locationsNCT04234048
Recruiting
Phase 2

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

New Diagnosed Angioimmunoblastic T-Cell Lymphoma
The Affiliated Hospital of Xuzhou Medical University40 enrolled1 locationNCT07168317
Recruiting
Phase 2

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

Angioimmunoblastic T-Cell Lymphoma RecurrentAngioimmunoblastic T-Cell Lymphoma Refractory
The Affiliated Hospital of Xuzhou Medical University40 enrolled1 locationNCT07058103